COVID-19 Vaccine Effectiveness Among Health Workers in Georgia (COV19HWVE_GE)

Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in Georgia

This is a prospective one-year cohort study of hospital-based health workers in Georgia to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection and COVID-19 disease.

Study Overview

• Status: Recruiting
• Conditions: Covid19
• Intervention / Treatment: Biological: Covid-19 vaccines

Detailed Description

Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.

This is a prospective one-year cohort study of hospital-based health workers in Georgia to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection and COVID-19 disease. Health Workers (HWs) are the target population in this study because they have been prioritized to be the first group to receive the vaccine in Georgia and offer an early opportunity to evaluate the vaccine in a population in which it is critical that an effective vaccine be deployed.

HWs should be enrolled after the study protocol is approved by the local ethical review committee. All HWs eligible to be vaccinated with COVID-19 vaccine can be enrolled in the study, including those who intend to get vaccinated, those who do not plan on getting vaccinated, and those who are not sure. For HWs who have already been vaccinated at enrolment, priority will be given to those who have received their first COVID vaccine no more than 4 days prior to the date of enrolment. The target enrolment is 1600 participants.

At enrolment, study participants will complete a baseline enrolment survey about demographics, clinical comorbidities, and work and community-related behaviors related to infection risk, and recent symptoms. In addition, a baseline serology will be collected from participants at enrolment.

For study participants who have not received their first COVID-19 vaccine at enrolment but receive their first vaccine 14 days or more after enrolment, an additional blood sample will be collected. In addition, a brief symptom questionnaire about recent symptoms will be administered.

During the course of the study, participants will be actively followed for suspected COVID-19 infection. Participants will be asked to complete weekly symptom questionnaires to screen for clinically significant COVID-19. Participants who meet a suspected case definition, defined according to the Georgian national case definition should provide a respiratory sample which will be collected by trained HW. Respiratory specimens will be tested for SARS-CoV-2 by RT-PCR.

All or subset of positive samples from study participants will undergo genetic sequencing, resources permitting.

Finally, after 3, 6, 9 and 12 months of the study, as resources permit, serology will be collected from participants. Serology will be tested for antibodies to SARS-CoV-2 by tests for vaccine-induced antibodies and antibodies that result from natural infection.

Vaccine effectiveness should be analysed as described in the analysis section below.

In addition to the final analysis at the end of the one-year period, interim quarterly (every three months) analyses will be undertaken.

• Study Type: Observational
• Enrollment (Anticipated): 1600

Contacts and Locations

• Study Contact: Name: Khatuna C Zakhashvili, MD; Phone Number: +995599317079; Email: episurv@ncdc.ge
• Study Contact Backup: Name: Lia Sanodze, MD; Phone Number: +995595993804; Email: l.sanodze@ncdc.ge

Study Locations

• Georgia
  • Tbilisi, Georgia, 0145
    • Recruiting
    • The Bokeria Tbilisi Referral Hospital
    • Contact: Nona C Beradze, MD; Phone Number: +995595956163; Email: n.beradze@ncdc.ge
    • Contact: Rusudan Chlikadze, MD; Phone Number: +995595956155; Email: r.chlikadze@ncdc.ge
  • Tbilisi, Georgia, 0160
    • Recruiting
    • Academician N. Kipshidze Central University Clinic
    • Contact: Tamar C Sulkhanishvili, MD; Phone Number: +995595956165; Email: t.sulkhanishvili@ncdc.ge
    • Contact: Ketevan Sanadze, MD; Phone Number: +995595956140; Email: k.sanadze@ncdc.ge
  • Tbilisi, Georgia, 0160
    • Recruiting
    • The Bochorishvili Clinic
    • Contact: Teona Kashibadze, MD; Phone Number: +995591152535; Email: t.kashibadze@ncdc.ge
    • Contact: Irma Burjanadze, MD; Phone Number: +995595956121; Email: i.burjanadze@ncdc.ge
  • Tbilisi, Georgia, 0160
    • Recruiting
    • The Infectious Diseases and AIDS Center
    • Contact: Teona Kashibadze; Phone Number: +995591152535; Email: t.kashibadze@ncdc.ge
    • Contact: Irma Burjanadze; Phone Number: +995595956121; Email: i.burjanadze@ncdc.ge
  • Tbilisi, Georgia, 0186
    • Recruiting
    • The Caucasus Medical Centre
    • Contact: Irina C Kalandadze, MD; Phone Number: +995595956151; Email: i.kalandadze@ncdc.ge
    • Contact: Pikria Shavreshiani, MD; Phone Number: +995595424314; Email: p.shavreshiani@ncdc.ge
  • Ajara
    • Batumi, Ajara, Georgia
      • Recruiting
      • The Batumi Republican Clinical Hospital
      • Contact: Nana Jintcharadze, MD; Phone Number: +995577278729; Email: nanajintcharadze22@gmail.com
      • Contact: Lia Varshalomidze, MD; Phone Number: +995577278728; Email: liavarshalomidze@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The study population will be composed of health workers in the above hospitals, eligible for vaccination, with no contraindication to receive COVID-19 vaccine. HWs include all categories of staff working in the hospitals, including clinical and non-clinical/administrative staff and staff with direct patient interaction and those without direct patient interaction. All HWs at the above hospitals who are eligible for vaccination, according to Ministry of Health guidelines, will be eligible for enrolment, regardless of their intention to receive the COVID-19 vaccine.

Description

Inclusion Criteria:

All HWs eligible to receive the COVID-19 vaccination according to the national guidelines of Ministry of Health (MoH).

• HWs working at Batumi Republican Clinical Hospital, Vakhtang Bochorishvili Clinic, Academician N. Kipshidze Central University Clinic, Bokeria Tbilisi Referral Hospital, Caucasus Medical Centre, and Infectious Diseases and AIDS Center.
• HWs who have already been vaccinated with a single dose of vaccine against COVID-19 as part of the early COVID-19 vaccine rollout can be included.

Exclusion Criteria:

• HWs who are not eligible for COVID-19 vaccination or have a contraindication to vaccination should not participate in the study.
• HWs who do not work at above mentioned hospitals
• HWs under 18 years of age.
• HWs who have already been vaccinated with two doses of vaccine against COVID-19 before enrolment

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Vaccinated participants; Participants who received 1or 2 doses of the Covid-19 vaccines	Biological: Covid-19 vaccines; Observation of individuals who received one or more doses of covid-19 vaccines.
Unvaccinated participants; Participants who have not received any dose of the Covid-19 vaccines

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Covid-19 vaccine effectiveness	any SARS-CoV-2 laboratory confirmation by RT-PCR in an asymptomatic, or symptomatic patient	12 months

Collaborators and Investigators

• Sponsor: National Center for Disease control and Public Health
• Collaborators: World Health Organization
• Investigators: Principal Investigator: Khatuna C Zakhashvili, MD, National Center for Disease control and Public Health

Study record dates

Study Major Dates

• Study Start (Actual): March 20, 2021
• Primary Completion (Anticipated): August 1, 2022
• Study Completion (Anticipated): August 1, 2022

Study Registration Dates

• First Submitted: April 29, 2021
• First Submitted That Met QC Criteria: April 29, 2021
• First Posted (Actual): May 3, 2021

Study Record Updates

• Last Update Posted (Actual): May 3, 2021
• Last Update Submitted That Met QC Criteria: April 29, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: Cohort study; Vaccine effectiveness; Georgia; Health workers
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: CERC.0097B

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No